<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002540</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01755</org_study_id>
    <secondary_id>NCI-2012-01755</secondary_id>
    <secondary_id>PLCO-1</secondary_id>
    <secondary_id>CDR0000078532</secondary_id>
    <secondary_id>PLCO-Prostate</secondary_id>
    <secondary_id>NCI-P93-0050</secondary_id>
    <nct_id>NCT00002540</nct_id>
  </id_info>
  <brief_title>Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)</brief_title>
  <official_title>Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This clinical trial studies whether screening methods used to diagnose cancer of the
      prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening
      tests may help doctors find cancer cells early and plan better treatment for prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether screening with digital rectal examination (DRE) plus serum
      prostate-specific antigen (PSA) can reduce mortality from prostate cancer in men aged 55-74
      at entry.

      SECONDARY OBJECTIVES:

      I. To assess screening variables, other than mortality, for each of the interventions
      including sensitivity, specificity, and positive predictive value.

      II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the
      mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as
      intermediate endpoints.

      IV. To conduct biomolecular and genetic research into factors associated with cancer
      carcinogenesis and promotion, as well as the early detection of these factors.

      OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender,
      and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms
      (control vs screening).

      ARM I (Control): Participants receive standard medical care. Participants complete a Diet
      History Questionnaire (DHQ) at baseline.

      ARM II (Prostate Screening): Participants undergo blood sample collection for PSA analysis at
      baseline and annually for 5 years. Serum that is not used in the study will be stored in an
      NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. A
      scheduling and tracking procedure is implemented to ensure regular attendance at repeat
      screens for participants screened negative or for those who are designated suspicious or
      positive at screening but for whom subsequent diagnostic procedures do not reveal prostate
      cancer (follow-up diagnostic procedures are through their own medical care environment).
      Participants diagnosed with prostate cancer via a screening test are referred for treatment
      in accordance with current accepted practice for appropriate stage of disease, patient age,
      and medical condition; a procedure is provided for contact with qualified medical personnel
      to insure appropriate therapy.

      Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual
      Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH]
      questionnaire) is mailed to each participant annually for 13 years to identify all prevalent
      and incident prostate cancers as all deaths that occur among both screened and control
      subjects during the trial.

      After completion of screening, participants are followed up for at least 13 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 1993</start_date>
  <primary_completion_date type="Actual">May 21, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate Cancer Deaths</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
    <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Cancer Death Rates</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
    <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deaths From All Causes</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009.</time_frame>
    <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death Rates From All Causes</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009.</time_frame>
    <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer Incidence</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
    <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer Incidence Rates</measure>
    <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
    <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test</measure>
    <time_frame>One year from screening examination</time_frame>
    <description>Number of positive screens with complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T0 (Baseline) PSA Screening Results</measure>
    <time_frame>T0 (at study entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T0 (Baseline) DRE Screening Results</measure>
    <time_frame>T0 (at study entry)</time_frame>
    <description>Digital Rectal Examination (DRE) result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1 PSA Screening Results</measure>
    <time_frame>T1 (one year after entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1 DRE Screening Results</measure>
    <time_frame>T1 (one year after entry)</time_frame>
    <description>Digital Rectal Examination (DRE) result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 PSA Screening Results</measure>
    <time_frame>T2 (two years after entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T2 DRE Screening Results</measure>
    <time_frame>T2 (two years after entry)</time_frame>
    <description>Digital Rectal Examination (DRE) results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T3 PSA Screening Results</measure>
    <time_frame>T3 (three years after entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T3 DRE Screening Results</measure>
    <time_frame>T3 (three years after entry)</time_frame>
    <description>Digital Rectal examination (DRE) result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T4 PSA Screening Result</measure>
    <time_frame>T4 (four years after entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T5 PSA Screening Results</measure>
    <time_frame>T5 (five years after entry)</time_frame>
    <description>Prostate-Specific Antigen (PSA) result.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76685</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive standard medical care. Participants complete a DHQ at baseline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate Screening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prostate Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medical Examination</intervention_name>
    <description>Undergo DRE</description>
    <arm_group_label>Prostate Screening</arm_group_label>
    <other_name>Exam</other_name>
    <other_name>Examination</other_name>
    <other_name>Medical Assessment</other_name>
    <other_name>Medical Exam</other_name>
    <other_name>Medical Inspection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening Questionnaire Administration</intervention_name>
    <description>Undergo questionnaire assessments</description>
    <arm_group_label>Prostate Screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  Men who at the time of randomization are less than 55 or greater than or equal to 75
             years of age

          -  Individuals undergoing treatment for cancer at this time, excluding basal-cell and
             squamous-cell skin cancer

          -  Individuals with known prior cancer of the colon, rectum, lung, prostate

               -  This includes primary or metastatic PLCO cancers

          -  Individuals with previous surgical removal of the entire colon, one lung, or the
             entire prostate

          -  Individuals who are participating in another cancer screening or cancer primary
             prevention trial

          -  Males who have taken Proscar/Propecia/finasteride in the past 6 months

               -  NOTE: Individuals who are already enrolled in the trial when their physician
                  prescribes finasteride are not prevented from taking this medication. As a
                  result, these participants will continue to be screened and followed just as
                  those participants who are not on finasteride.

               -  NOTE: Men who are taking Tamoxifen are not excluded from any part of the PLCO
                  Screening Trial.

          -  Individuals who are unwilling or unable to sign the informed consent form

          -  Males who have had more than one PSA blood test in the past three years

          -  Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past
             three years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Berg</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2004</study_first_posted>
  <results_first_submitted>August 30, 2013</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2014</results_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between November 1993 and July 2001 at 10 study centers. Recruitment was done for all four outcomes of the study (prostate, lung, colorectal and ovarian).</recruitment_details>
      <pre_assignment_details>Participants signed a study informed consent prior to being randomized to a study arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Participants receive standard medical care.</description>
        </group>
        <group group_id="P2">
          <title>Prostate Screening</title>
          <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38345"/>
                <participants group_id="P2" count="38340"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37544"/>
                <participants group_id="P2" count="35876"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="801"/>
                <participants group_id="P2" count="2464"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Cancer Before Rand. (Prostate Screening)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Died Before Randomization</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Died Before ASU (Control)</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused ASU (Control)</title>
              <participants_list>
                <participants group_id="P1" count="597"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Screen (Prostate Screening)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2433"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Participants receive standard medical care.</description>
        </group>
        <group group_id="B2">
          <title>Prostate Screening</title>
          <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38345"/>
            <count group_id="B2" value="38340"/>
            <count group_id="B3" value="76685"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24390"/>
                    <measurement group_id="B2" value="24400"/>
                    <measurement group_id="B3" value="48790"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13955"/>
                    <measurement group_id="B2" value="13940"/>
                    <measurement group_id="B3" value="27895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="5.3"/>
                    <measurement group_id="B2" value="62.7" spread="5.3"/>
                    <measurement group_id="B3" value="62.7" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38345"/>
                    <measurement group_id="B2" value="38340"/>
                    <measurement group_id="B3" value="76685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38345"/>
                    <measurement group_id="B2" value="38340"/>
                    <measurement group_id="B3" value="76685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prostate Cancer Deaths</title>
        <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
        <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Deaths</title>
          <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.</description>
          <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deaths From All Causes</title>
        <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009.</time_frame>
        <population>All male participants were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Deaths From All Causes</title>
          <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm.</description>
          <population>All male participants were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7089"/>
                    <measurement group_id="O2" value="6855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death Rates From All Causes</title>
        <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009.</time_frame>
        <population>All male participants were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Death Rates From All Causes</title>
          <description>Deaths from all causes were compared between the prostate cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.</description>
          <population>All male participants were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Deaths per 10,000 PY</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.6"/>
                    <measurement group_id="O2" value="160.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Cancer Incidence</title>
        <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
        <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Incidence</title>
          <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
          <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3815"/>
                    <measurement group_id="O2" value="4250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Cancer Incidence Rates</title>
        <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
        <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Incidence Rates</title>
          <description>Prostate cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as prostate cancer diagnoses divided by person years at risk for prostate cancer.</description>
          <population>All male participants randomized were analyzed. An intention-to-treat analysis was performed.</population>
          <units>Diagnoses per 10,000 PY</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="108.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test</title>
        <description>Number of positive screens with complications</description>
        <time_frame>One year from screening examination</time_frame>
        <population>The units analyzed were positive screening exams with documented diagnostic follow-up. If a participant received 3 positive screens with documented follow-up after each one, he would be counted 3 times in the number of units analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test</title>
          <description>Number of positive screens with complications</description>
          <population>The units analyzed were positive screening exams with documented diagnostic follow-up. If a participant received 3 positive screens with documented follow-up after each one, he would be counted 3 times in the number of units analyzed.</population>
          <units>Positive screens w/ complications</units>
          <param>Number</param>
          <units_analyzed>Positive Screens with Follow-up</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10642"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Positive Screens with Follow-up</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>When DE Led to Prostate Cancer Diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>When DE Did Not Lead to Prostate Cancer Diagnosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T0 (Baseline) PSA Screening Results</title>
        <description>Prostate-Specific Antigen (PSA) result.</description>
        <time_frame>T0 (at study entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T0 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T0 (Baseline) PSA Screening Results</title>
          <description>Prostate-Specific Antigen (PSA) result.</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T0 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (&lt;=4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T0 (Baseline) DRE Screening Results</title>
        <description>Digital Rectal Examination (DRE) result.</description>
        <time_frame>T0 (at study entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a DRE screen at T0 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T0 (Baseline) DRE Screening Results</title>
          <description>Digital Rectal Examination (DRE) result.</description>
          <population>All males in the Prostate Screening arm who had a DRE screen at T0 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1 PSA Screening Results</title>
        <description>Prostate-Specific Antigen (PSA) result.</description>
        <time_frame>T1 (one year after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T1 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T1 PSA Screening Results</title>
          <description>Prostate-Specific Antigen (PSA) result.</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T1 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32688"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (&lt;=4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1 DRE Screening Results</title>
        <description>Digital Rectal Examination (DRE) result.</description>
        <time_frame>T1 (one year after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a DRE screen at T1 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T1 DRE Screening Results</title>
          <description>Digital Rectal Examination (DRE) result.</description>
          <population>All males in the Prostate Screening arm who had a DRE screen at T1 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T2 PSA Screening Results</title>
        <description>Prostate-Specific Antigen (PSA) result.</description>
        <time_frame>T2 (two years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T2 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T2 PSA Screening Results</title>
          <description>Prostate-Specific Antigen (PSA) result.</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T2 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31691"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T2 DRE Screening Results</title>
        <description>Digital Rectal Examination (DRE) results</description>
        <time_frame>T2 (two years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a DRE screen at T2 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T2 DRE Screening Results</title>
          <description>Digital Rectal Examination (DRE) results</description>
          <population>All males in the Prostate Screening arm who had a DRE screen at T2 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T3 PSA Screening Results</title>
        <description>Prostate-Specific Antigen (PSA) result</description>
        <time_frame>T3 (three years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T3 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T3 PSA Screening Results</title>
          <description>Prostate-Specific Antigen (PSA) result</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T3 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (&lt;=4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T3 DRE Screening Results</title>
        <description>Digital Rectal examination (DRE) result</description>
        <time_frame>T3 (three years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a DRE screen at T3 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T3 DRE Screening Results</title>
          <description>Digital Rectal examination (DRE) result</description>
          <population>All males in the Prostate Screening arm who had a DRE screen at T3 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Cancer Death Rates</title>
        <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.</description>
        <time_frame>Events through 13 years of follow-up or through December 31, 2009; median follow-up 12.0 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Participants receive standard medical care.</description>
          </group>
          <group group_id="O2">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Death Rates</title>
          <description>Prostate cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.</description>
          <units>Deaths per 10,000 PY</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38345"/>
                <count group_id="O2" value="38340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T4 PSA Screening Result</title>
        <description>Prostate-Specific Antigen (PSA) result</description>
        <time_frame>T4 (four years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T4 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T4 PSA Screening Result</title>
          <description>Prostate-Specific Antigen (PSA) result</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T4 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (&lt;=4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T5 PSA Screening Results</title>
        <description>Prostate-Specific Antigen (PSA) result.</description>
        <time_frame>T5 (five years after entry)</time_frame>
        <population>All males in the Prostate Screening arm who had a PSA screen at T5 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Prostate Screening</title>
            <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
          </group>
        </group_list>
        <measure>
          <title>T5 PSA Screening Results</title>
          <description>Prostate-Specific Antigen (PSA) result.</description>
          <population>All males in the Prostate Screening arm who had a PSA screen at T5 were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25951"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative (&lt;=4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive (&gt; 4 ng/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inadequate screen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each annual screening visit.</time_frame>
      <desc>These events are solely those prompted by the screening examination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Prostate Screening</title>
          <description>Participants undergo blood sample collection for prostate specific antigen (PSA) analysis at baseline and annually for 5 years. Participants also undergo a digital rectal examination (DRE) at baseline and annually for 3 years.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="546" subjects_at_risk="38340"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" events="108" subjects_affected="101" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Fainted</sub_title>
                <counts group_id="E1" events="59" subjects_affected="58" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="183" subjects_affected="182" subjects_at_risk="38340"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="190" subjects_affected="187" subjects_at_risk="38340"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul F. Pinsky, Ph.D.</name_or_title>
      <organization>Early Detection Research Group, NCI, NIH</organization>
      <phone>301-496-8544</phone>
      <email>pinskyp@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

